Indian Researchers Identify Key Protein That Helps Colorectal Cancer Withstand Chemotherapy

 May 26, 2026

KANPUR, INDIA — In a major breakthrough for personalized oncology, researchers at the Indian Institute of Technology Kanpur (IIT-K), in collaboration with teams from the Tata Memorial Centre in Mumbai, King George’s Medical University (KGMU) in Lucknow, and the Henry Ford Health System in the United States, have identified a specific cellular protein that enables colorectal cancer cells to resist standard chemotherapy.

The study, published in the peer-reviewed journal Nature Communications, reveals that a protein known as dyskerin pseudouridine synthase 1 (DKC1) plays a central role in helping tumors survive aggressive drug regimens. The landmark findings suggest that DKC1 could serve as both a crucial biomarker to predict treatment resistance and a novel therapeutic target, offering new hope for tailored, more effective cancer therapies.

Colorectal cancer, which encompasses malignancies of both the colon and the rectum, stands as one of the leading causes of cancer-related mortality worldwide. It is also an escalating public health crisis in India, driven by shifting dietary habits, physical inactivity, and rising lifestyle-related risk factors. While standard chemotherapy regimens are initially effective for many, tumors frequently develop resistance over time. Once a tumor becomes drug-resistant, clinical options narrow significantly, and patient survival rates drop sharply. This new discovery provides medical professionals with a critical tool to identify high-risk patients much earlier in their treatment cycle.

What the Study Found: The Role of DKC1

The multi-institutional research team, spearheaded by Prof. Bushra Ateeq from the Department of Biological Sciences and Bioengineering at IIT-K, focused their investigation on DKC1. Historically, this protein was recognized by biologists primarily for its housekeeping roles in basic cellular mechanics, such as cellular aging and overall cell growth.

However, by utilizing a rigorous combination of laboratory models and retrospective analyses of human patient tissue, the researchers uncovered a darker side to the protein: high concentrations of DKC1 are directly tied to aggressive tumor behavior and a poor response to standard chemotherapy.

During laboratory experiments, the scientists successfully demonstrated that reducing DKC1 levels or chemically blocking its associated signaling pathways yielded two major results:

• Suppressed Growth: It noticeably slowed down the proliferation and spread of the tumor cells.

• Restored Sensitivity: It made the stubborn cancer cells highly vulnerable once again to standard chemotherapy agents, specifically those utilized in the FOLFOX regimen—the frontline chemotherapy cocktail commonly prescribed for colorectal cancer patients.

When evaluating human tissue samples, the clinical correlation became undeniable. Patients whose tumors exhibited high levels of DKC1 expression tended to present with more advanced stages of the disease and experienced significantly lower overall survival rates. This dual finding firmly positions DKC1 as both a reliable prognostic marker and a potential “handhold” for future drug development.

How DKC1 Acts as a “Survival Switch”

To understand why DKC1 makes colorectal cancer so resilient, it helps to look at how healthy cells behave. Under normal circumstances, the human body regulates cell life through a tightly controlled process of programmed cell death called apoptosis. When a cell becomes heavily damaged or abnormal, apoptosis acts as an internal self-destruction sequence, protecting the rest of the body from malignant growths. Chemotherapy relies heavily on triggering this self-destruction sequence by severely stressing the cancer cells.

The IIT-K study revealed that elevated levels of DKC1 effectively jam this self-destruction machinery. Even when flooded with toxic chemotherapy drugs, the cancer cells bypass the apoptosis trigger and continue to survive.

Beyond blocking cell death, DKC1 acts like an internal metabolic engineer, completely rewiring how tumor cells process fats (lipids). Specifically, the protein dysregulates the biosynthesis of sphingolipids—a specialized class of fat molecules that are vital for maintaining cell membrane structure and controlling internal cellular communication. By altering this lipid profile, DKC1 creates a protective chemical shield around the tumor cells, allowing them to withstand drug-induced stress and replicate at an accelerated pace. In essence, the protein functions as a molecular “survival switch” that reprograms the tumor’s internal chemistry to defy standard medicine.

Why This Matters for Public Health and Daily Treatment

Chemotherapy resistance remains one of the most formidable barriers in modern oncology. Many individuals diagnosed with colorectal cancer respond well to initial interventions, only to experience a aggressive recurrence that no longer responds to standard care.

If testing for DKC1 levels can be successfully standardized and integrated into routine pathology, oncologists will be able to stratify patients immediately upon diagnosis. Those identified with high DKC1 expression could be fast-tracked to intensive, alternative, or targeted therapies right from the start, sparing them the grueling physical toll and lost time associated with ineffective treatments.

“This discovery can pave the way for redesigning the treatment strategy for colorectal cancer patients who are not responding to conventional chemotherapy drugs,” Prof. Bushra Ateeq stated in an official release detailing the breakthrough.

The research team envisions a future where standard chemotherapy cocktails are paired with newly developed inhibitors designed specifically to block DKC1 or its altered lipid pathways, thereby restoring the tumor’s vulnerability to treatment.

Dr. Aarati Rao, a surgical oncologist who was not involved in the study, expressed optimistic caution regarding its clinical integration.

“If DKC1 proves to be a reliable biomarker in larger, multi-center prospective trials, it could fundamentally change our workflow,” Dr. Rao told Health News Portal. “It could dramatically reduce the time we spend administering drugs that are biologically destined to fail in certain patients, allowing us to pivot to newer, targeted options much sooner.”

Context Within Global Cancer Research

The rising incidence of colorectal cancer in developing nations has made it a top priority for national health frameworks. While global researchers have previously identified other molecular culprits behind drug resistance—such as heat-shock proteins and complex DNA-repair networks—DKC1 introduces an entirely new pathway to the scientific map.

This study builds upon other recent oncology milestones. For instance, recent research from late 2025 highlighted how the cystine/glutamate transporter system ($Xc^-$) and its associated protein, SLC7A11, help colon tumors cope with oxidative stress to avoid cell death. The IIT-K discovery adds a complementary piece to this complex biological puzzle. By illustrating how lipid metabolism and dyskerin proteins cooperate to shield cancer, the study opens up multi-faceted avenues for potential “drug cocktails” that attack tumor resistance from several angles simultaneously.

Current Limitations and Challenges

Despite the excitement surrounding the findings, independent medical experts urge the public to view the discovery with a balanced perspective. The research is currently in its early, largely preclinical stages. The conclusions are drawn from controlled laboratory models and historical, retrospective patient data.

Before DKC1 testing can be adopted into mainstream clinical practice, its safety and efficacy must be validated through prospective clinical trials—meaning researchers must actively use DKC1 levels to guide real-time treatment decisions in living patients and measure whether it genuinely extends survival.

Dr. Neha Singh, a medical oncologist specializing in gastrointestinal malignancies, emphasized this need for rigorous validation.

“DKC1 is undoubtedly an exciting new lead, but it is one of several potential biomarkers currently under the microscope,” Dr. Singh noted. “Before it becomes part of the standard of care, we absolutely need robust, prospective human data showing that targeting this protein actually improves patient survival without adding unacceptable levels of toxicity.”

What This Means for Patients and Families

For individuals currently navigating a colorectal cancer diagnosis, or those with a strong family history of the disease, this breakthrough highlights two crucial shifts in modern medicine:

1. The Rise of Personalized Oncology: Cancer care is rapidly moving away from a “one-size-fits-all” model. Treatments are increasingly tailored to the unique genetic and molecular fingerprint of an individual’s tumor.

2. The Vital Importance of Early Detection: Because tumor cells evolve and develop sophisticated resistance mechanisms the longer they grow, detecting colorectal cancer early remains the single best defense for successful intervention.

From a practical standpoint, as molecular tumor profiling becomes more widespread, patients and their caregivers can use this research to guide active conversations with their healthcare teams. When discussing diagnostic workups, helpful questions to ask an oncologist include:

• Will my tumor undergo molecular or biomarker profiling, and does it include looking at proteins associated with therapy resistance?

• If a tumor exhibits high resistance markers, how does that alter our long-term treatment strategy or choice of chemotherapy?

• Are there active clinical trials evaluating targeted therapies or combination treatments for drug-resistant profiles?

Medical authorities emphasize that these findings should not prompt any patient to alter or question their current treatment. Standard clinical guidelines—such as the FOLFOX regimen—remain highly effective for a vast majority of patients and remain the absolute anchor of modern colorectal cancer care.

References

• https://health.economictimes.indiatimes.com/news/industry/iit-k-researchers-identify-protein-enabling-colorectal-cells-withstand-chemotherapy/131270737?utm_source=top_story&utm_medium=homepage

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.